RxDoctor Payments Data

Ciara Antolin, NP

Nurse Practitioner · Lynchburg, VANPI 1740047703

Payments from drug & device makers

$1,690in general payments, 2019–2025

Across 22 payments — averaging $76.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$444
  • Amgen$171
  • AbbVie$154
  • Novo Nordisk$130
  • Lundbeck LLC$121
  • BETA Bionics, Inc.$119
  • plus $552 from 7 others

What the payments were for

  • Food & beverage$1,67499%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,690 in reported general payments places this provider in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$19,681
Medicare patients
121
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$176,117
TrulicityDulaglutide53$55,956
JardianceEmpagliflozin46$45,854
MounjaroTirzepatide41$45,499
FarxigaDapagliflozin Propanediol24$30,200
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$19,598
Insulin Lispro Kwikpen U-100Insulin Lispro35$19,026
Humalog Kwikpen U-100Insulin Lispro45$17,139
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$13,906
JanuviaSitagliptin Phosphate16$13,772
Novolog FlexpenInsulin Aspart21$9,420
Nano 2nd Gen Pen NeedlePen Needle, Diabetic33$4,259
Glipizide22$177
Metformin Hcl22$154
Metformin Hcl ErMetformin Hcl23$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$176,117127 claims
MerckJanuvia$110$13,77216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →